» Articles » PMID: 9736530

Pharmacokinetics and Distribution over the Blood-brain Barrier of Zalcitabine (2',3'-dideoxycytidine) and BEA005 (2', 3'-dideoxy-3'-hydroxymethylcytidine) in Rats, Studied by Microdialysis

Overview
Specialty Pharmacology
Date 1998 Sep 16
PMID 9736530
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Microdialysis was applied to sample the unbound drug concentration in the extracellular fluid in brain and muscle of rats given zalcitabine (2',3'-dideoxycytidine; n = 4) or BEA005 (2', 3'-dideoxy-3'-hydroxymethylcytidine; n = 4) (50 mg/kg of body weight given subcutaneously). Zalcitabine and BEA005 were analyzed by high-pressure liquid chromatography with UV detection. The maximum concentration of zalcitabine in the dialysate (Cmax) was 31.4 +/- 5. 1 microM (mean +/- standard error of the mean) for the brain and 238. 3 +/- 48.1 microM for muscle. The time to Cmax was found to be from 30 to 45 min for the brain and from 15 to 30 min for muscle. Zalcitabine was eliminated from the brain and muscle with half-lives 1.28 +/- 0.64 and 0.85 +/- 0.13 h, respectively. The ratio of the area under the concentration-time curve (AUC) (from 0 to 180 min) for the brain and the AUC for muscle (AUC ratio) was 0.191 +/- 0.037. The concentrations of BEA005 attained in the brain and muscle were lower than those of zalcitabine, with Cmaxs of 5.7 +/- 1.4 microM in the brain and 61.3 +/- 12.0 microM in the muscle. The peak concentration in the brain was attained 50 to 70 min after injection, and that in muscle was achieved 30 to 50 min after injection. The half-lives of BEA005 in the brain and muscle were 5.51 +/- 1.45 and 0.64 +/- 0.06 h, respectively. The AUC ratio (from 0 to 180 min) between brain and muscle was 0.162 +/- 0.026. The log octanol/water partition coefficients were found to be -1.19 +/- 0.04 and -1.47 +/- 0.01 for zalcitabine and BEA005, respectively. The degrees of plasma protein binding of zalcitabine (11% +/- 4%) and BEA005 (18% +/- 2%) were measured by microdialysis in vitro. The differences between zalcitabine and BEA005 with respect to the AUC ratio (P = 0.481), half-life in muscle (P = 0.279), and level of protein binding (P = 0.174) were not statistically significant. The differences were statistically significant in the case of the half-life in the brain (P = 0.032), clearance (P = 0.046), volume of distribution (P = 0.027) in muscle, and octanol/water partition coefficient (P = 0.019).

Citing Articles

The antiretroviral 2',3'-dideoxycytidine causes mitochondrial dysfunction in proliferating and differentiated HepaRG human cell cultures.

Young C, Wheeler J, Rahman M, Young M J Biol Chem. 2020; 296:100206.

PMID: 33334881 PMC: 7948951. DOI: 10.1074/jbc.RA120.014885.


2',3'-Dideoxycytidine Protects Dopaminergic Neurons in a Mouse Model of Parkinson's Disease.

Niu J, Xiong J, Hu D, Zeng F, Nie S, Mao S Neurochem Res. 2017; 42(10):2996-3004.

PMID: 28631231 DOI: 10.1007/s11064-017-2330-9.


Antiretroviral bioanalysis methods of tissues and body biofluids.

Difrancesco R, Maduke G, Patel R, Taylor C, Morse G Bioanalysis. 2013; 5(3):351-68.

PMID: 23394701 PMC: 3836712. DOI: 10.4155/bio.12.319.


A recursive-partitioning model for blood-brain barrier permeation.

Mente S, Lombardo F J Comput Aided Mol Des. 2005; 19(7):465-81.

PMID: 16331406 DOI: 10.1007/s10822-005-9001-7.


Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue.

Muller M, dela Pena A, Derendorf H Antimicrob Agents Chemother. 2004; 48(5):1441-53.

PMID: 15105091 PMC: 400530. DOI: 10.1128/AAC.48.5.1441-1453.2004.


References
1.
Collins J, Klecker Jr R, Kelley J, Roth J, McCully C, Balis F . Pyrimidine dideoxyribonucleosides: selectivity of penetration into cerebrospinal fluid. J Pharmacol Exp Ther. 1988; 245(2):466-70. View

2.
Stahle L, Mian A, Borg N . Use of multivariate characterization, design and analysis in assay optimization. J Pharm Biomed Anal. 1995; 13(4-5):369-76. DOI: 10.1016/0731-7085(95)01327-h. View

3.
Klecker Jr R, Collins J, Yarchoan R, Thomas R, McAtee N, Broder S . Pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS and related disorders. J Clin Pharmacol. 1988; 28(9):837-42. DOI: 10.1002/j.1552-4604.1988.tb03225.x. View

4.
Broder S . Pharmacodynamics of 2',3'-dideoxycytidine: an inhibitor of human immunodeficiency virus. Am J Med. 1990; 88(5B):2S-7S. DOI: 10.1016/0002-9343(90)90413-8. View

5.
Stahle L, Segersvard S, Ungerstedt U . Theophylline concentration in the extracellular space of the rat brain: measurement by microdialysis and relation to behaviour. Eur J Pharmacol. 1990; 185(2-3):187-93. DOI: 10.1016/0014-2999(90)90639-n. View